Company Description Cancer science / neuro-oncology / cancer neuroscience / glioblastoma / therapy resistance / longitudinal proteogenomics / spatio-temporal multi-omics / translational cancer therapy,
Dr. Sung Kim is a cancer scientist with expertise in neuro-oncology, cancer neuroscience, glioblastoma biology, therapy resistance, tumor recurrence, and translational cancer research. His research focuses on understanding how malignant tumors adapt to therapeutic pressure, undergo molecular and cellular reprogramming, and acquire recurrence-competent phenotypes research through strong collaboration with National Cancer Center (South Korea), Havard medical center (USA), Cleveland Clinic (USA), and NCI (USA).
His work integrates cancer biology, neuroscience, longitudinal disease modeling, and proteogenomic approaches to investigate the mechanisms that drive treatment resistance and recurrence in aggressive brain tumors. His current scientific interests include glioblastoma recurrence, therapy-induced tumor plasticity, anti-angiogenic therapy resistance, hypoxia-driven adaptation, mitochondrial stress responses, tumor microenvironmental remodeling, and spatio-temporal proteogenomic programs that emerge before clinically detectable recurrence.
Dr. Kim has contributed to high-impact studies in glioblastoma, cancer stem cell biology, tumor-associated macrophage remodeling, mitochondrial adaptation, mesenchymal transition, and therapy resistance. His research has been supported by competitive grants, including funding for longitudinal proteogenomic analysis of recurrence potential factors and preclinical validation of therapeutic antibodies in glioblastoma models. He is also interested in translational cancer therapy strategies, including immunotherapy and CAR-T cell-based approaches, particularly when integrated with molecular profiling to identify actionable vulnerabilities in cancer.
Role Description Potential MSCA Postdoctoral Fellowship applicants are invited to develop a project within the broader field of cancer science, neuro-oncology, and therapy resistance. Possible research topics include, but are not limited to:
1. Spatio-temporal proteogenomics of glioblastoma/pan cancer recurrence
This project would investigate how glioblastoma evolves during therapeutic response and recurrence by integrating longitudinal proteomic, transcriptomic, phosphoproteomic, and spatially resolved molecular profiling approaches.
2. Therapy-induced adaptation and recurrence commitment in glioblastoma/pan cancer
This project would examine how therapeutic pressure induces adaptive tumor states before clinically visible recurrence, with the goal of identifying early molecular programs that define recurrence-competent cancer cells.
3. Hypoxia-driven tumor plasticity and targeted therapy resistance
This project would focus on how hypoxia and targeted therapy reshape glioblastoma/pan cancer biology, including mitochondrial adaptation, neuronal-like reprogramming, microenvironmental/immune remodeling, and resistant tumor evolution.
4. Mitochondrial stress responses as therapeutic vulnerabilities in recurrent brain tumors
This project would investigate mitochondrial metabolism, mitochondrial dynamics, stress adaptation, and mitochondrial–immune–tumor communication as mechanisms of survival and recurrence under therapeutic pressure.
5. Tumor microenvironment remodeling during cancer therapy response
This project would explore how immune cells, extracellular matrix remodeling, vascular adaptation, hypoxic niches, and neuronal or synaptic-like programs contribute to therapy resistance and tumor recurrence.
6. Molecular profiling-guided therapeutic strategies for aggressive cancers
This project would aim to connect proteogenomic or multi-omics profiling with therapeutic vulnerability discovery, including targeted therapy, immunotherapy, antibody-based therapy, or CAR-T-related translational strategies.
Applicants are encouraged to propose their own project ideas within these themes, particularly if they bring complementary expertise in cancer biology, neuroscience, molecular oncology, computational biology, spatial biology, immunology, or translational therapeutic development.
Qualifications
The applicant should be highly/strongly motivated, scientifically independent, collaborative, and capable of developing a competitive MSCA Postdoctoral Fellowship proposal together with the supervisor.
- Transcriptomic, proteomic, phosphoproteomic, spatial omics, or single-cell data analysis, including WES and clonal evolution.
- Bioinformatics, statistical analysis, R/Python-based data analysis, or multi-omics integration
- Scientific writing, independent project development, and preparation of manuscripts or grant applications
or/and
- Glioblastoma, brain tumor biology, neuro-oncology, or cancer therapy resistance
- Tumor hypoxia, mitochondrial biology, metabolism, or stress adaptation
- Cell culture, patient-derived models, organoids, or preclinical tumor models
- Molecular biology techniques, including qPCR, western blotting, immunofluorescence, immunohistochemistry, flow cytometry, or related approaches
- Immunotherapy, antibody-based therapy, CAR-T cell approaches, or cancer therapeutic development
15 July – 25 July 2026, Earlier members will have highly original research projecst with the potential to generate high-impact publications.
Employment Type
Full-time
Pay: $10,000.00 - $20,000.00 per month
Benefits:
- Paid parental leave
- Relocation assistance
Work Location: In person
